Skip to main content
. 2019 May 27;20(10):2592. doi: 10.3390/ijms20102592

Figure 6.

Figure 6

Effects of HH-F3 on fibrogenesis markers and the TGF-β pathway from the in vivo model. Rats were divided into five groups. One group served as the untreated control, one group was treated with DEN to induce liver fibrosis, and the other groups were cotreated with DEN and sorafenib or different doses of HH-F3 (50 mg/kg/day and 150 mg/kg/day) orally (oral administration, P.O.) every day. Rats were sacrificed and the liver tissues were homogenized followed by Western blot analysis and quantification. (A) HH-F3 reduced fibrogenesis markers in a DEN-induced liver fibrosis model. (B) HH-F3 inhibited the TGF-β pathway in a DEN-induced liver fibrosis model. * p < 0.05, ** p < 0.01 compared to the DEN group; # p < 0.05 compared to the normal group.